Sam Brusco, Associate Editor01.02.24
SimBioSys, a company using spatial biophysics with artificial intelligence (AI) and biophysical monitoring to redefine precision medicine for cancer, began a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions for breast cancer patients.
The duo said their aim is to build cloud-based clinical software tools to support end-to-end decision making for early-stage breast cancer patients—including individualized surgical planning, treatment, drug selection, and risk stratification.
SimBioSys has both had access to and has been analyzing data from patients who participated in Mayo Clinic’s BEAUTY clinical trial. The company said it will perform simulations using previously gathered data and perform in-silico scenario analysis, guided by the team at Mayo Clinic.
SimBioSys’ TumorSight, a SaMD cloud-based platform, will be used in the clinic during treatment planning. The company’s first product on the TumorSight platform is currently under U.S. Food and Drug Administration (FDA) review. It takes a patient’s DCE-MRI imaging to create a custom, 3D digital model of their tumor.
The tool offers surgical oncologists 3D spatial visualizations of breast cancer to support surgical planning and consultations. “Digital twin” renderings show the tumor in the context of auto-segmented anatomical structures: skin, vessels, chest, fat, gland, and heart.
"In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care," said Tushar Pandey, co-founder and CEO of SimBioSys. "SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”
The duo said their aim is to build cloud-based clinical software tools to support end-to-end decision making for early-stage breast cancer patients—including individualized surgical planning, treatment, drug selection, and risk stratification.
SimBioSys has both had access to and has been analyzing data from patients who participated in Mayo Clinic’s BEAUTY clinical trial. The company said it will perform simulations using previously gathered data and perform in-silico scenario analysis, guided by the team at Mayo Clinic.
SimBioSys’ TumorSight, a SaMD cloud-based platform, will be used in the clinic during treatment planning. The company’s first product on the TumorSight platform is currently under U.S. Food and Drug Administration (FDA) review. It takes a patient’s DCE-MRI imaging to create a custom, 3D digital model of their tumor.
The tool offers surgical oncologists 3D spatial visualizations of breast cancer to support surgical planning and consultations. “Digital twin” renderings show the tumor in the context of auto-segmented anatomical structures: skin, vessels, chest, fat, gland, and heart.
"In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care," said Tushar Pandey, co-founder and CEO of SimBioSys. "SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”